Sugi Predict

Sugi Predict / Compounds / SCHEMBL110879

SCHEMBL110879

SCHEMBL110879

COC(=O)c1cc(Br)nc2c3ccc(OC)cc3n(Cc3ccccc3)c12

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2A P14555 11/20 0.53
▸ MTNR1A P48039 2/20 0.52
▸ MTNR1B P49286 2/20 0.52
▸ PLA2G10 O15496 1/20 0.48
▸ PLA2G1B P04054 1/20 0.48
▸ TP53 P04637 2/20 0.47
▸ MAPK8 P45983 1/20 0.47
▸ MAPT P10636 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ CNR2 P34972 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL145790 0.87 CCR2 (0.46) PLA2G2ATP53MAPK8MAPTHDAC1
SCHEMBL110525 0.83 PLA2G2A (0.48) PLA2G2AMTNR1AMTNR1BPLA2G10PLA2G1B
SCHEMBL110330 0.80 L3MBTL1 (0.46) PLA2G2ATP53MAPTHDAC1HDAC8
SCHEMBL143937 0.72 PPARG (0.44) PLA2G2ATP53
SCHEMBL143205 0.71 PLA2G2A (0.49) PLA2G2ATP53MAPT
SCHEMBL3659423 0.71 CCR2 (0.63) PLA2G2AMTNR1AMTNR1BPLA2G10PLA2G1B
SCHEMBL8356414 0.70 LMNA (0.70) PLA2G2AMTNR1AMTNR1BPLA2G1BCNR2
SCHEMBL7963970 0.70 PLA2G2A (1.00) PLA2G2APLA2G10PLA2G1B
SCHEMBL141523 0.69 PLA2G2A (0.47) PLA2G2ATP53MAPT
SCHEMBL4885587 0.69 PLA2G10 (0.64) PLA2G2AMTNR1AMTNR1BPLA2G10PLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 — — US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 — — US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 — — US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 — — EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 — — EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 PLA2G2A 4509/4885MTNR1A 1739/4885MTNR1B 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.